Compare Quest Diagnostics Inc (DGX) vs JPMorgan Equity Premium Income ETF (JEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs JPMorgan Equity Premium Income ETF — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while JPMorgan Equity Premium Income ETF trades at $56.77 (market cap $45.55B). The key difference: JPMorgan Equity Premium Income ETF is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while JPMorgan Equity Premium Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and JPMorgan Equity Premium Income ETF for 57 Days on average.
| DGX | JEPI | |
|---|---|---|
Market Cap | $25.48B | $45.55B |
Volume | 941,866 | 3,820,809 |
Sector | Health | Income / Options Overlay |
52-Week High | $247.45 | $59.88 |
52-Week Low | $173.49 | $55.29 |
Typical Hold Time | 56 Days | 57 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
JEPI trades at $56.79, up 0.6% with a bearish technical signal from moving averages. The ETF shows neutral momentum oscillators and key support at $56. Recent dividend activity includes three distributions averaging $0.36 per share through August-October 2026. Media coverage focuses on income generation strategies and tax implications for retirement portfolios.
The covered-call strategy provides consistent income but may limit upside during market rallies. Institutional interest remains strong with recent position increases. Key risks include interest rate sensitivity and the trade-off between yield and capital appreciation potential in rising markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →
